Market Overview

Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space

Share:
Why The Novartis-AveXis Deal Is Good News For The Gene Therapy Space

AveXis Inc (NASDAQ: AVXS) announced Monday its sale to Novartis AG (ADR) (NYSE: NVS) for $8.7 billion, or $218 per share.

The deal didn’t come as a complete surprise.

The Rating

Chardan analyst Gbola Amusa maintained a Buy rating on AveXis and increased the price target from $140 to $218.

The Thesis

Amusa previously predicted AveXis’ acquisition on the basis of faith in the firm’s lead candidate, AVXS-101, the analyst said. Separately, he anticipated Novartis’ emergence as a consolidator in the AAV-based gene therapy space.

The combined prophecies are expected to merge with the deal’s closure in mid-2018, and Amusa forecast a couple implications for the industry.

For one, Novartis will have proven its position as a consolidator in genetic medicine, the analyst said. 

“We expect Novartis to acquire or partner further in AAV-based ophthalmology gene therapy," Amusa said in a Monday note. He mentioned Spark Therapeutics Inc (NASDAQ: ONCE), Nightstar Therapeutics PLC (NASDAQ: NITE) or Regenxbio Inc (NASDAQ: RGNX) as potential targets.

At the same time, the process and final price to secure AveXis is considered an industry positive.

“An 88-percent premium to us suggests other parties were bidding on AveXis, which to us means unfulfilled demand for GT assets,” the analyst said. “We believe the price paid also reflects a supportive view by Novartis on the risk of systemic toxicity for AAV-based gene therapies.”

Novartis plans to issue a tender offer by April 17.

Price Action

AveXis popped after hours on the news and, at time of publication, traded up 82 percent off Friday’s close to $209.60 a share.

Related Links:

Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy

5 Reasons Why Vuzix Is One Of Chardan Capital's Top Picks In 2018

Latest Ratings for NVS

DateFirmActionFromTo
Apr 2019UpgradesNeutralBuy
Apr 2019DowngradesEqual-WeightUnderweight
Dec 2018AssumesBuy

View More Analyst Ratings for NVS
View the Latest Analyst Ratings

Posted-In: Analyst Color Biotech M&A News Health Care Price Target Reiteration Top Stories Best of Benzinga

 

Related Articles (NITE + AVXS)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
HSKACanaccord GenuityMaintains75.0
AVGOMorgan StanleyMaintains265.0
AMATNeedhamMaintains56.0
VOYACitigroupMaintains62.0
VCCitigroupMaintains86.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

Benzinga's Top Upgrades, Downgrades For April 9, 2018

The Market In 5 Minutes: Deutsche Bank, GM, Trump, WrestleMania And More